close

TranS1 Inc., a medical device company, focuses on the design, development, and marketing of products that implement its proprietary surgical approach to treat degenerative disc disease and instability affecting the lower lumbar region of the spine. The company offers TranS1 pre-sacral approach to allow spine surgeons to access and treat degenerative lumbar discs, as well as to perform fusion and motion preserving surgeries in the L4/L5/S1 region. Its products include AxiaLIF lumbar fusion implant, a threaded titanium rod to enable one-level L5/S1 fusions and two-level L4/L5/S1 fusions; AxiaLIF 360° implants, which consist of 3D Axial Rod plus its titanium facet screws for supplemental posterior fixation; and TranS1 access and disc preparation instruments. The company also focuses on developing two products that implement its TranS1 approach, including percutaneous nucleus replacement and partial disc replacement devices. It markets and sells its products through direct sales representatives and independent sales agents in the United States, as well as primarily through third-party distributors in Europe. The company was formerly known as aXiaMed, Inc. and changed its name to TranS1 Inc. in February 2003. TranS1 Inc. was founded in 2000 and is headquartered in Wilmington, North Carolina.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	3.41
Volume	76755
Volume Avg	182234
52 Week High	5.42
52 Week Low	1.39
PE	N/A
PE (group average)	N/A
EPS Year	-0.81
EPS change Q/Q	0%
EPS change Q/Q Yr ago	-12.9%
EPS change Q/Q next Q est	-58.82%
EPS change Y/Y	-32.22%
REV change Q/Q	-13.56%
REV change Q/Q Yr ago	-23.88%
EPS next Q est	-0.17
EPS next Y est	-0.59
Divident Annual	0.00
Dividend Yield	0%